VERTEX PHARMACEUTICALS INC

25 December, 2024

Vertex Pharmaceuticals Faces Stock Volatility Following Mixed Clinical Trial Results Despite Strong Cystic Fibrosis Portfolio

Vertex Pharmaceuticals has had a volatile year in 2023, with its stock rising 27% primarily due to the success of its cystic fibrosis (CF) treatment, Trikafta. However, the company faced a significant...
Read More

24 December, 2024

Vertex Pharmaceuticals Faces Stock Decline Amid Mixed Phase 2 Study Results for Pain Drug Suzetrigine, But Analysts Remain Optimistic About Future Growth and FDA Approvals

Vertex Pharmaceuticals recently faced stock declines exceeding 12% after mixed results from a phase 2 clinical trial of suzetrigine, a non-opioid treatment targeting lumbosacral radiculopathy. Despite...
Read More

23 December, 2024

Vertex Pharmaceuticals Stock Drops 14% Despite Meeting Primary Endpoint in Phase 2 Study for Non-Opioid Pain Drug Suzetrigine

Vertex Pharmaceuticals recently experienced a notable decline in its stock following disappointing results from a Phase 2 study of its non-opioid drug, suzetrigine, aimed at treating lumbosacral radic...
Read More

22 December, 2024

Vertex Pharmaceuticals' Stock Plummets Over 10% Following Mixed Results for Non-Opioid Pain Drug Suzetrigine

Vertex Pharmaceuticals has faced significant market challenges following the recent Phase 2 trial results for its non-opioid pain drug, suzetrigine, which were released in December 2024. Despite the t...
Read More